Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement

Evaxion A/S filed an amendment to its F-1 registration statement related to a July 2025 debt settlement agreement with the European Investment Bank (EIB). Under the agreement, EIB converted €3.5 million of debt into warrants for 38.45 million shares at $4.87 per ADS. The conversion provided Evaxion with immediate €3.5 million equity increase and potential additional proceeds of approximately $1.5 million from warrant exercises, strengthening the company's capital structure and financial flexibility.

11/09/2026, 8:00 AM • GlobeNewswire

New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Evaxion announced new phase 2 biomarker data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, demonstrating potent neoantigen-specific T-cell responses and validating the predictive performance of its AI-Immunology™ platform. The data showed 89% vaccine target precision with sustained clinical responses at three-year follow-up, including a 75% objective response rate at two years.

11/06/2026, 11:00 AM • GlobeNewswire

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

Evaxion A/S, a clinical-stage TechBio company, has won the 2026 International Prix Galien Award for its AI-Immunology platform as the best digital health solution, marking the first time a Danish company has received this prestigious award. The recognition follows positive three-year phase 2 trial data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, which demonstrated 89% vaccine target precision and sustained T-cell responses.

10/30/2026, 4:00 AM • GlobeNewswire

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed.

10/02/2026, 9:00 AM • GlobeNewswire

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion announced new preclinical data supporting its multi-component cytomegalovirus (CMV) vaccine candidate EVX-V1, which combines AI-discovered antigens with optimized established antigens. The data demonstrates potential to improve control of acute infection, latency, and viral reactivation. EVX-V1 represents a scalable strategy for rational vaccine development across herpesviruses, addressing a significant unmet medical need as no CMV vaccine is currently licensed despite affecting 60-70% of adults in developed countries.

07/12/2026, 9:30 AM • GlobeNewswire

Evaxion receives Prix Galien UK Award for Best digital health solution

Evaxion A/S received the 2026 Prix Galien UK Award for Best Digital Health Solution for its AI-Immunology™ platform, which uses artificial intelligence to develop novel vaccine candidates for cancer and infectious diseases. This marks the company's second recognition from the Galien Prix Foundation in less than a year, validating the platform's capabilities in vaccine target discovery and development.

06/12/2026, 3:00 AM • GlobeNewswire

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion announced positive preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). The vaccine successfully expresses and secretes in human cells, drives specific immune responses across different human immune profiles, and induces targeted cell-killing. The company is preparing regulatory filings for clinical testing and will present the data at the European Hematology Association Congress in Stockholm on June 13, 2026.

06/11/2026, 2:00 AM • GlobeNewswire

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

Evaxion A/S announced the promotion of Birgitte Rønø to serve as both Chief Scientific Officer and Chief Operating Officer, reflecting her extensive contributions to the company's operations and scientific expertise. The move is intended to enhance external engagement and strategy execution while strengthening the company's ability to communicate its AI-Immunology™ platform capabilities to partners and investors.

04/27/2026, 8:00 AM • GlobeNewswire

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Evaxion announced data demonstrating its AI-Immunology platform can identify endogenous retrovirus (ERV)-derived antigens for glioblastoma vaccine design, in collaboration with Duke University. The findings show ERVs as a novel antigen source that could overcome limitations from low mutational burden in brain cancer, with results to be presented at the AACR Annual Meeting in April 2026.

04/17/2026, 3:00 PM • GlobeNewswire

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Evaxion has completed the one-year extension of its phase 2 trial for EVX-01, a personalized cancer vaccine for advanced melanoma. The trial demonstrated a 75% Objective Response Rate with 92% of patients still responding at two-year follow-up. Three-year clinical efficacy data is expected in the second half of 2026.

04/07/2026, 8:00 AM • GlobeNewswire

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Evaxion has developed novel polio vaccine design concepts using its AI-Immunology™ platform in collaboration with the Gates Foundation. The company will present these concepts, along with data from its EVX-V1 cytomegalovirus vaccine program, at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026. The new polio vaccine designs aim to combine the strengths of existing vaccines while addressing their individual shortcomings.

03/30/2026, 8:00 AM • GlobeNewswire

Notice to convene Evaxion’s Annual General Meeting

Evaxion A/S, a clinical-stage TechBio company, announced its Annual General Meeting scheduled for April 16, 2026, at its Copenhagen offices. The company continues developing novel vaccines using its AI-Immunology™ platform for cancer and infectious diseases, with a clinical pipeline of personalized and off-the-shelf vaccine candidates.

03/19/2026, 9:00 AM • GlobeNewswire

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company, will report its full year 2025 financial results and provide a business update on March 5, 2026. The company will host a conference call and webcast at 14:30 CET/08:30 EST to present results and discuss its AI-Immunology™ platform development for cancer vaccines, infectious disease vaccines, and newly expanded autoimmune disease applications.

03/02/2026, 8:00 AM • GlobeNewswire

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Evaxion A/S announced expansion of its AI-Immunology platform to include autoimmune diseases as a third disease area alongside cancer and infectious diseases. The company outlined 2026 milestones including biomarker data for EVX-01, autoimmune disease application development, three-year phase 2 efficacy data, and regulatory filings. Cash runway extends to second half of 2027. Additionally, MSD declined to exercise its option on the Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to out-license it to other partners.

01/13/2026, 8:00 AM • GlobeNewswire

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Merck & Co. has decided not to exercise its option for Evaxion's gonorrhea vaccine candidate EVX-B2 (protein-based version), allowing Evaxion to retain global rights and seek alternative licensing partners. The decision does not impact Evaxion's cash runway extending to mid-2027. Evaxion continues developing an mRNA version with Afrigen Biologics and previously out-licensed EVX-B3 to Merck in September for $7.5 million upfront plus up to $592 million in milestone payments.

12/19/2025, 12:43 PM • Benzinga